Your search
Results 3 resources
-
Introduction: Letermovir is a cytomegalovirus (CMV) terminase complex inhibitor approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic cell transplantation (allo-HCT) recipients (R+). We report pharmacokinetics (PK), safety, and efficacy of letermovir in adolescent (12–18 years) allogeneic HCT recipients from an ongoing clinical study. Methods: In this phase 2b, multicenter, open-label study (NCT03940586), 28...
-
Valganciclovir for 200 days is standard care for cytomegalovirus (CMV) prophylaxis in high-risk CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor, but its use is limited by myelosuppression.To compare the efficacy and safety of letermovir with valganciclovir for prevention of CMV disease in CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor.Randomized, double-masked, double-dummy, noninferiority,...
Filter by our tag
ORGANISMS
-
VIRUSES
(3)
-
CMV
(3)
- Letermovir (3)
-
CMV
(3)
DRUGS AND THERAPIES
- Antivirals (1)
HEME-ONC AND CELLULAR THERAPIES
- Heme-onc prophylaxis (1)
- PEDIATRIC (1)
ATC 2024 Top Papers in TID
- VIRUSES (1)